Question | Answers from the laboratory side | Answers from clinicians |
---|---|---|
Elements on the request form | Which elements do you often miss? N = 18 | Which elements do you always enter? N = 28 |
Primary diagnosis | 3 (17%) | 28 (100%) |
Previous tests performed | 3 (17%) | 12 (43%) |
Original activating mutation | 7 (39%) | 19(68%) |
Previous therapies | 9 (50%) | 11 (39%) |
Tumor stage | 4 (22%) | 12 (43%) |
Type of progression | 4 (22%) | 7 (25%) |
Time of progression | 3 (17%) | 0 (0%) |
Clinical question (reason for testing) | 9 (50%) | 21 (75%) |
In an ideal world: who is allowed to request additional tests? | N= 21 | N= 24 |
Only pathologist | 2 (10%) | 2 (8%) |
Pathologist and clinician | 18 (86%) | 20 (83%) |
Only clinician | 1 (5%) | 2 (8%) |
Other | 0 (0%) | 0 (0%) |
Current situation: who is allowed to request additional tests? | N= 18 | N= 24 |
Only pathologist | 1 (6%) | 4 (17%) |
Pathologist and clinician | 9 (50%) | 15 (63%) |
Only clinician | 7 (39%) | 5 (21%) |
Other (depends on the initial requester) | 1 (6%) | 0 (0%) |
Which of the following items regarding the request form are important? | N= 0 | N= 6 |
The request form is dedicated for molecular testing | - | 4 (67%) |
The request form is dedicated for specific cancer types | - | 5 (83%) |
An online version of the request form is available | - | 0 (0%) |
The indications for testing are indicated on the request form | - | 6 (100%) |
The testing techniques are indicated on the request form | - | 6 (100%) |
The tissue/blood recipient is indicated on the request form | - | 5 (83%) |
The transport medium is indicated on the request form | - | 4 (67%) |
The max delay for transport is mentioned on the request form | - | 4 (67%) |
What is the reporting flow in your hospital? | N= 18 | N= 7 |
1 integrated report: biomarker results are added when available—WITH a conclusion per biomarker—WITH a conclusion on ALL biomarkers at the end | 6 (33%) | 3 (43%) |
1 integrated report: biomarker results are added when available—WITH a conclusion per biomarker—WITHOUT a conclusion on ALL biomarkers at the end | 8 (44%) | 4 (57%) |
1 integrated report: biomarker results are added when available—WITHOUT a conclusion per biomarker—WITH a conclusion on ALL biomarkers at the end | 0 (0%) | 0 (0%) |
Separate reports are released for each biomarker result | 3 (17%) | 0 (0%) |
Other | 1 (6%) | 0 (0%) |
How do you receive the report? | N= 0 | N= 7 |
On paper | - | 3 (43%) |
Via email | - | 1 (14%) |
Via the hospital information system | - | 6 (86%) |
Via telephone | - | 0 (0%) |
Other | - | 0 (0%) |
Question | Answers from the laboratory side | Answers from clinicians |
Elements on the result report | What do you think the clinician needs on the report? N = 19 | What do you read on the report? N = 28 |
Clinical interpretation | 14 (74%) | 27 (96%) |
Description of the analytical method | 1 (5%) | 13 (46%) |
Sensitivity of the test method | 8 (42%) | 13 (46%) |
% neoplastic cells | 4 (21%) | 27 (96%) |
Genotyping result | 3 (16%) | 18 (64%) |
Tested regions of the target gene (e.g. which exons) | 3 (16%) | 15 (54%) |
Variant allelic frequency | 0 (0%) | 1 (4%) |
Is it in your hospital appreciated by the clinician to give an interpretation on the test report? | N = 4 | N = 4 |
Yes, as a general interpretation (e.g. In general, patients with the L858R mutation in EGFR are sensitive to 1st and 2nd generation anti-EGFR TKI.) | 3 (75%) | 1 (25%) |
Yes, as a direct advice (e.g. This patient has a L858R mutation in EGFR and should be treated with a 1st generation anti-EGFR TKI) | 0 (0%) | 2 (50%) |
Yes, both as a general interpretation or direct advice | 0 (0%) | 1 (25%) |
No, the clinician wants to make the interpretation | 0 (0%) | 0 (0%) |
No, but for difficult cases the report is discussed with the clinician | 0 (0%) | 0 (0%) |
I don't know | 1 (25%) | 0 (0%) |
Are some biomarker tests outsourced by your hospital? | N = 6 | N = 3 |
Yes | 5 (83%) | 3 (100%) |
No | 0 (0%) | 0 (0%) |
I don’t know | 1 (17%) | 0 (0%) |
What is the TAT for biomarker testing for NSCLC in your hospital? | N = 6 | N = 3 |
1–7 days | 2 (33%) | 3 (100%) |
8–14 days | 4 (67%) | 0 (0%) |
15–21 days | 0 (0%) | 0 (0%) |
What is the TAT for biomarker testing for NSCLC when tests are outsourced? | N = 5 | N = 3 |
1–7 days | 0 (0%) | 0 (0%) |
8–14 days | 5 (100%) | 3 (100%) |
15–21 days | 0 (0%) | 0 (0%) |